A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
← catalyst calendarNCT07037771 · readout in 366 d
Sponsored by Arrowhead Pharmaceuticals (industry) · ARWR — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
70actual
Sites
43
Countries
Australia, Austria, Belgium +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-17 | actual | When the study began enrolling |
| Primary completion | 2027-08-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Homozygous Familial Hypercholesterolemia
Interventions
- Drug: zodasiran Injection — also filed as ARO-ANG3
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period)
measured Baseline, Month 12
Permalink · ARWR's whole pipeline · Catalyst calendar · Every registered study · What changed